Sangamo Therapeutics - Genome Editing's Unit Acquisition

Sangamo Therapeutics - Genome Editing raised a round of funding on February 22, 2018. Investors include Kite Pharma.

Sangamo Therapeuticsm aka Sangamo BioSciences, of Richmond, CA, is focused on the research and development of novel transcription factors for the regulation of gene expression. The company's most adva…

Articles about Sangamo Therapeutics - Genome Editing's Unit Acquisition: